In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Silver Lining for British Biotech and ImmunoGen

Executive Summary

British Biotech acquired EU and Japanese rights to ImmunoGen's preclinical cancer compound, huN901-DM1. As part of the deal, British Biotech also will be responsible, on a contract basis, for US clinical development of the drug. ImmunoGen retains US product rights, allowing it to establish the drug's value before out-licensing. For British Biotech, which has reorganized, the deal is typical of its new strategy of emphasizing its development capabilities, acting in a CRO-like manner for other companies. ImmunoGen is also enjoying something of a renaissance, having inked two deals with Genentech, which will apply ImmunoGen technology to develop monoclonal antibody/drug conjugates.
Advertisement

Related Content

UK Biotech Learns the Hard Way

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel